Lisa Simpson is Vice President of Clinical Operations and Compliance at Visus Therapeutics. She brings with her more than 25 years of experience in clinical research with a focus in ophthalmology.  Prior to joining Visus, Lisa was Vice President of R&D Compliance for AbbVie and Allergan where she had oversight of healthcare compliance policies, training and monitoring for all R&D functions and Therapeutic Areas including Ophthalmology, Gastroenterology, Central Nervous System, Medical Aesthetics, Women’s Health, and Anti-Infectives. Prior to this, Lisa spent over 18 years at various roles within the ophthalmology clinical operations team at Allergan including the Head of Clinical Operations for Ophthalmology and Core Team Leader for DURYSTA™, a novel form of glaucoma treatment.  During her time at Allergan, she supported the development and approval of ophthalmic products for the front and back of the eye, including: ACUVAIL®, ALPHAGAN® P 0.1%, COMBIGAN®, DURYSTA™, GANFORT®, LUMIGAN® 0.01%, OZURDEX®, REFRESH® BRAND (OTC), RESTASIS MULTIDOSE®, TRIPLIGAN®, XEN® Gel Stent, and ZYMAXID®.  

Lisa holds an MBA from the University of California, Irvine, and a BA in Cognitive Science from the University of California, Berkeley.  Lisa is also a Certified Clinical Research Associate.